Rare though not mutually exclusive: A report of three cases of concomitant kras and braf mutation and a review of the literatuer

Ibrahim Halil Sahin, Syed M A Kazmi, Jeffrey T. Yorio, Nishin A. Bhadkamkar, Bryan K. Kee, Christo pher R Garrett

Research output: Contribution to journalArticle

32 Scopus citations


KRAS mutations occur frequently in colorectal cancers (CRC) and predict lack of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy. CRC BRAF muta-tions, most commonly at V600E, occur less than 10% of the time, and occur usually in KRAS wild-type tumors, and more frequently in microsatellite instable tumors. Concomitant KRAS and BRAF mutant CRCs are rare (occurring in 0.001%); BRAF mutations should not be routinely tested in patients with KRAS mutant tumors, unless the patients is participating in a clinical trial enriching for the presence of a KRAS or BRAF tumor. Clinical trials treating patients with either KRAS or BRAF mutant tumors should address eligibility ofpatients with concomitant KRAS and BRAF mutations.

Original languageEnglish (US)
Pages (from-to)320-322
Number of pages3
JournalJournal of Cancer
Issue number4
Publication statusPublished - Aug 30 2013



  • BRAF
  • Concomitant KRAS

ASJC Scopus subject areas

  • Oncology

Cite this